Showing results (441-450 of 514) with videos related to

Sort By:
Pageof 52
Bioorganic & Medicinal Chemistry Letters|December 26, 2006
Thienopyridine urea inhibitors of KDR kinaseH Robin Heyman, Robin R Frey, Peter F Bousquet, et al.
Bone Marrow Transplantation|October 26, 2010
Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use programK Hübel, M M Fresen, H Salwender, et al.
Blood|July 24, 2024
Interleukin-1 blockade in patients with Wiskott-Aldrich syndrome: a retrospective multinational case seriesSamuele Naviglio, Maria Pia Cicalese, Elizabeth Rivers, et al.
Leukemia|September 13, 2022
Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trialAnna Eichinger, Ulrike Poetschger, Evgenia Glogova, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 6, 2022
ESTRO ACROP and SIOPE recommendations for myeloablative Total Body Irradiation in childrenBianca A W Hoeben, Montserrat Pazos, Enrica Seravalli, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 2012
Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase familiesKeith B Glaser, Junling Li, Patrick A Marcotte, et al.
Blood|April 22, 2016
The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosisBernd Hartz, Rebecca Marsh, Kanchan Rao, et al.
Haematologica|February 13, 2016
Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemiaSandra Preuner, Christina Peters, Ulrike Pötschger, et al.
Bioorganic & Medicinal Chemistry Letters|June 20, 2001
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770M L Curtin, A S Florjancic, H R Heyman, et al.
Cancer Research|April 19, 2017
Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic StrategiesMai H Bui, Xiaoyu Lin, Daniel H Albert, et al.
Pageof 52